drugset / Trial / NCT05273671

Nalbuphine Versus Dexmedetomidine for Prevention of Emergence Agitation in Pediatrics

NCT05273671

Phase 4 Unknown 126 enrolled Alexandria University
RandomizedParallel-groupTriple-blindPrevention

Summary

the investigators hypothesized that Nalbuphine may be alternative pharmacological agent for prevention of emergence agitation in pediatrics who will be scheduled for elective lower abdominal surgical procedures (inguinal hernia repair and hypospadias) during sevoflurane anesthesia

Timeline

Start
2022-03-01
Primary completion
2022-06-01
Completion
2022-06-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg Intravenous
Subject Nalbuphine Small molecule 0.1 mg/kg Intravenous

Indications

No indication recorded.